KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to 72267.92%.

  • Vir Biotechnology's EBIT Margin fell 625492600.0% to 72267.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 3253.6%, marking a year-over-year decrease of 24789300.0%. This contributed to the annual value of 791.27% for FY2024, which is 27700.0% up from last year.
  • As of Q3 2025, Vir Biotechnology's EBIT Margin stood at 72267.92%, which was down 625492600.0% from 9754.28% recorded in Q2 2025.
  • Vir Biotechnology's EBIT Margin's 5-year high stood at 82.26% during Q1 2022, with a 5-year trough of 72267.92% in Q3 2025.
  • In the last 5 years, Vir Biotechnology's EBIT Margin had a median value of 828.12% in 2023 and averaged 6583.54%.
  • Per our database at Business Quant, Vir Biotechnology's EBIT Margin soared by 81102500bps in 2022 and then tumbled by -625492600bps in 2025.
  • Over the past 5 years, Vir Biotechnology's EBIT Margin (Quarter) stood at 70.35% in 2021, then tumbled by -533bps to 304.6% in 2022, then crashed by -172bps to 828.12% in 2023, then decreased by -14bps to 946.74% in 2024, then tumbled by -7533bps to 72267.92% in 2025.
  • Its EBIT Margin was 72267.92% in Q3 2025, compared to 9754.28% in Q2 2025 and 4602.47% in Q1 2025.